Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.18 HKD | -1.51% | -0.55% | -6.02% |
03-29 | 3D Medicines' 2023 Loss Almost Halves as Revenue Jumps 12% | MT |
03-28 | 3D Medicines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2021 | 60.26 470.36 4.74K | Sales 2022 | 567.39 4.43K 44.59K | Capitalization | 8.38B 65.43B 659B |
---|---|---|---|---|---|
Net income 2021 | -1.43B -11.19B -113B | Net income 2022 | -1.02B -7.99B -80.47B | EV / Sales 2021 * | - |
Net Debt 2021 | 2.37B 18.48B 186B | Net cash position 2022 | 766M 5.98B 60.22B | EV / Sales 2022 | 13,423,339 x |
P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.67
x | Employees | 198 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 0% |
1 day | -1.51% | ||
1 week | -0.55% | ||
Current month | +9.79% | ||
1 month | +29.14% | ||
3 months | +12.36% | ||
6 months | -19.60% | ||
Current year | -6.02% |
Managers | Title | Age | Since |
---|---|---|---|
Zhao Long Gong
CEO | Chief Executive Officer | 60 | 31/12/13 |
Jing Zhang
DFI | Director of Finance/CFO | 50 | 27/08/20 |
Zhi Qiang Xue
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Tat Pang Lin
BRD | Director/Board Member | 67 | 30/11/22 |
Xin Guang Liu
BRD | Director/Board Member | 63 | 24/06/21 |
Zhao Long Gong
CEO | Chief Executive Officer | 60 | 31/12/13 |
Date | Price | Change | Volume |
---|---|---|---|
22/05/24 | 7.18 | -1.51% | 1 001 000 |
21/05/24 | 7.29 | -8.30% | 2,265,442 |
20/05/24 | 7.95 | +5.86% | 3,945,500 |
17/05/24 | 7.51 | +4.02% | 7,334,000 |
16/05/24 | 7.22 | +2.27% | 2,839,000 |
Delayed Quote Hong Kong S.E., May 22, 2024 at 09:08 am
More quotes1st Jan change | Capi. | |
---|---|---|
-6.02% | 212M | |
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-2.36% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |
- Stock Market
- Equities
- 1244 Stock